Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Inclusion criteria: 1. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation 2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea. 3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of \>7.0% and \< or = 10% at Visit 1 (screening) 4. Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study) 5. Age \> or =18 years at Visit 1 (screening) 6. BMI \< or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening) Exclusion criteria: 1. Patients with poorly controlled hyperglycemia 2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy 3. MI, stroke, or TIA within 3 months prior to obtaining informed consent 4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias 6\. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse